Recruitment closed MAY 2015
Trial Status: Complete
This is phase 1 multi-centre dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.
- To establish maximum tolerated dose of AZD8931 in combination with Xelox chemotherapy and define the safety of the combination and safety of post-operative AZD8931 maintenance therapy.
- Also to assess early efficacy data as determined by progression free survival (PFS) at 6 months and complete resection rate (R0). Pharmacodynamic biomarkers including blood, tissue and imaging will also be investigated to help select a patient population for further studies.
The primary results publication for the study can be found here.